Evan Lipson is Associate Professor of Oncology at Johns Hopkins University. OpenAlex indexes 373 publications with 22,120 citations (h-index 57); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Evan Lipson, MD, is Associate Professor of Oncology at Johns Hopkins University (Sidney Kimmel Comprehensive Cancer Center / Bloomberg-Kimmel Institute for Cancer Immunotherapy). The public record shows 373 publications with 22,120 citations (h-index 57), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 17 companies.
- Most recent indexed publication: 2026 · Cancer immunology research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 36 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 108.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Sponsor: National Cancer Institute (NCI)
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Sponsor: National Cancer Institute (NCI)
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 27 Aug 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202521 payments$20,144openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202512 payments
- ARRAY BIOPHARMA INCProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
57.1%Corticosteroid57.1%Hydrocortisone100%Part D<11 patientsCancer & immunology
42.9%Mitogen-activated protein kinase (MEK) inhibitors42.9%Mektovi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
47 congress contributions (2014–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 6456: Pan-tumor investigation of peripheral biomarkers of excellent response to anti-PD(L)1-based therapy
AACR Annual Meeting
AACR2026Co-author - Abstract LB419: Dose escalation and expansion of nivolumab plus relatlimab (NIVO + RELA) in solid tumors in RELATIVITY 020 Parts A-C
AACR Annual Meeting
AACR2026Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.
Cancer immunology research
Article2026 - Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
Journal for immunotherapy of cancer
Article2026 - AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery.
Journal for immunotherapy of cancer
Article2025 - International real-world study of combination immunotherapy sequences in metastatic melanoma.
Journal for immunotherapy of cancer
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma1,246 citations2016
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/evanlipson
- Doximity
doximity.com/pub/evan-lipson-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- X / Twitter
X (Twitter) handle @evanlipson
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Member
American Society for Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
Society for Melanoma Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
Society for Immunotherapy of Cancer (SITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Media & interviews
press, podcasts and appearances- Regular contributor/expert panelist
"Leading Thoughts: Melanoma" multimedia forum, Oncology News Central
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologynewscentral.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University